Categories
October Surprise 2024

Phase 4 Data Support Effectiveness of Deutetrabenazine in …

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.